c-MET Degrading Bispecific Antibody

About EpiBiologics

EpiBiologics is a private, preclinical-stage biotech pioneering extracellular targeted protein degradation (TPD). The company's modular EpiTAC platform leverages a novel atlas of over 270 tissue-enriched 'degrader receptors' to design bispecific antibodies that selectively degrade membrane and extracellular proteins in specific cell types. Founded in 2020 and based in San Diego, the company is advancing a pipeline in oncology and immunology, backed by significant venture capital, including a $107M Series B round closed in early 2026. EpiBiologics aims to address the ~40% of the proteome considered inaccessible to traditional TPD approaches.

Therapeutic Areas